United Therapeutics (NASDAQ:UTHR) Given New $425.00 Price Target at HC Wainwright

United Therapeutics (NASDAQ:UTHR) had its price objective raised by HC Wainwright from $400.00 to $425.00 in a report published on Thursday, Benzinga reports. They currently have a buy rating on the biotechnology company’s stock.

A number of other research analysts also recently weighed in on the company. Wells Fargo & Company raised their price objective on United Therapeutics from $350.00 to $380.00 and gave the company an “overweight” rating in a research note on Tuesday, August 20th. Argus lifted their price target on shares of United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a research report on Thursday. Oppenheimer boosted their price objective on shares of United Therapeutics from $400.00 to $575.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 28th. TD Cowen raised their target price on shares of United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a research note on Monday, October 21st. Finally, StockNews.com raised shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, United Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $370.86.

United Therapeutics Stock Performance

Shares of UTHR opened at $374.02 on Thursday. The firm has a market cap of $16.70 billion, a PE ratio of 16.43, a PEG ratio of 1.35 and a beta of 0.56. The firm’s 50 day moving average price is $355.40 and its 200 day moving average price is $317.24. United Therapeutics has a twelve month low of $208.62 and a twelve month high of $377.92.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, beating analysts’ consensus estimates of $6.16 by $0.23. The business had revenue of $748.90 million for the quarter, compared to the consensus estimate of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. United Therapeutics’s revenue for the quarter was up 22.9% on a year-over-year basis. During the same quarter last year, the firm earned $5.38 EPS. On average, sell-side analysts anticipate that United Therapeutics will post 24.85 earnings per share for the current fiscal year.

Insider Activity at United Therapeutics

In other news, CEO Martine A. Rothblatt sold 3,600 shares of United Therapeutics stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $325.45, for a total transaction of $1,171,620.00. Following the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at approximately $42,308.50. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, COO Michael Benkowitz sold 25,000 shares of the company’s stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $323.38, for a total value of $8,084,500.00. Following the sale, the chief operating officer now owns 2,577 shares of the company’s stock, valued at $833,350.26. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Martine A. Rothblatt sold 3,600 shares of the stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $325.45, for a total transaction of $1,171,620.00. Following the completion of the transaction, the chief executive officer now directly owns 130 shares of the company’s stock, valued at $42,308.50. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 98,412 shares of company stock worth $33,971,508 over the last three months. Company insiders own 11.90% of the company’s stock.

Institutional Investors Weigh In On United Therapeutics

Large investors have recently modified their holdings of the stock. LSV Asset Management boosted its stake in United Therapeutics by 82.5% in the 2nd quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company’s stock valued at $307,837,000 after buying an additional 436,851 shares in the last quarter. Swedbank AB bought a new position in shares of United Therapeutics during the first quarter valued at $97,316,000. Nordea Investment Management AB boosted its stake in shares of United Therapeutics by 677.6% in the 1st quarter. Nordea Investment Management AB now owns 300,920 shares of the biotechnology company’s stock valued at $72,422,000 after purchasing an additional 262,222 shares in the last quarter. Canada Pension Plan Investment Board grew its holdings in shares of United Therapeutics by 567.2% in the 1st quarter. Canada Pension Plan Investment Board now owns 180,800 shares of the biotechnology company’s stock worth $41,533,000 after purchasing an additional 153,700 shares during the last quarter. Finally, Assetmark Inc. increased its position in shares of United Therapeutics by 56.9% during the 3rd quarter. Assetmark Inc. now owns 419,957 shares of the biotechnology company’s stock worth $150,492,000 after purchasing an additional 152,249 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.